Bicycle Therapeutics Plc (BCYC) Financial Statements

Income statement

Metric	TTM	2025	2024	2023	2022
Revenue
Total Revenue	83.5M	72.6M	35.3M	27.0M	14.5M
Cost of Revenue	47.5M	—	173.0M	156.5M	—
Gross Profit	36.0M	72.6M	(137.7M)	(129.5M)	14.5M
Operating Expenses
R&D Expense	175.3M	240.3M	173.0M	156.5M	81.6M
SG&A Expense	66.6M	80.0M	71.5M	59.8M	49.5M
General & Admin Expense	66.6M	80.0M	71.5M	59.8M	49.5M
Selling & Marketing Expense	—	—	—	—	—
Other Expenses	—	—	(172.2M)	(155.9M)	—
Total Operating Expenses	241.8M	320.3M	72.2M	60.4M	131.1M
Cost and Expenses	241.8M	320.3M	245.1M	216.9M	131.1M
Operating Income (EBIT)	(158.3M)	(247.7M)	(209.9M)	(189.9M)	(116.7M)
Non-Operating
Interest Income	19.3M	28.5M	34.3M	14.0M	5.8M
Interest Expense	194.0K	206.0K	1.7M	3.3M	3.3M
Net Interest Income	19.1M	28.3M	32.6M	10.7M	2.4M
Other Non-Op Income/Expense	19.2M	28.9M	36.1M	10.7M	2.4M
Non-Operating Income (excl Interest)	(19.4M)	(29.1M)	(37.8M)	(14.0M)	(5.8M)
EBT (Pre-Tax Income)	(139.1M)	(218.8M)	(173.8M)	(179.2M)	(114.2M)
Income Tax Expense	2.7M	152.0K	(4.8M)	1.5M	(1.5M)
Bottom Line
Net Income	(141.8M)	(219.0M)	(169.0M)	(180.7M)	(112.7M)
Earnings from Cont. Ops	(141.8M)	(219.0M)	(169.0M)	(180.7M)	(112.7M)
Earnings from Discont. Ops	—	—	—	—	—
Bottom Line Net Income	(141.8M)	(219.0M)	(169.0M)	(180.7M)	(112.7M)
Per Share
Basic EPS	($2.03)	($3.16)	($2.91)	($5.08)	($3.80)
Diluted EPS	($2.03)	($3.16)	($2.90)	($5.08)	($3.80)
Revenue Per Share	$1.19	$1.05	$0.61	$0.76	$0.49
Shares
Basic Shares Outstanding	70.0M	69.3M	58.2M	35.6M	29.7M
Diluted Shares Outstanding	70.0M	69.3M	58.2M	35.6M	29.7M
Profitability Metrics
EBITDA	(134.3M)	(212.2M)	(164.9M)	(169.4M)	(107.2M)
D&A	4.6M	6.4M	7.2M	6.5M	3.7M
EBIT	(138.9M)	(218.6M)	(172.1M)	(175.9M)	(110.9M)

As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Sep 1, 2026